Social interaction and social withdrawal in rodents as readouts for investigating the negative symptoms of schizophrenia

European Neuropsychopharmacology

Volumn 24, Issue 5, 2014, Pages 759-773

  Wilson, Christina A ^a   Koenig, James I ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Negative symptoms; Rodent model; Schizophrenia; Social interaction; Social withdrawal

Indexed keywords

AMPHETAMINE; ANXIOLYTIC AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DIAZEPAM; DIZOCILPINE; HALOPERIDOL; KETAMINE; NEUROLEPTIC AGENT; OLANZAPINE; OXYTOCIN; PHENCYCLIDINE; PSYCHEDELIC AGENT; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

ARTICLE; BEHAVIOR; DOSE RESPONSE; DRUG EFFICACY; EMPATHY; HUMAN; INTERPERSONAL COMMUNICATION; LONG TERM CARE; NEGATIVE SYNDROME; NERVE CELL DIFFERENTIATION; NEUROBIOLOGY; NONHUMAN; PLACE PREFERENCE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL; RECOGNITION; RODENT MODEL; SCHIZOPHRENIA; SOCIAL INTERACTION; TASK PERFORMANCE; ANIMAL; BRAIN; DISEASE MODEL; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; RODENT; SOCIAL BEHAVIOR;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; NEUROPSYCHOLOGICAL TESTS; RODENTIA; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL BEHAVIOR;

EID: 84899854823     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.11.008     Document Type: Article

References (155)

1. Adkins-Regan E. Neuroendocrinology of social behavior. ILAR J. 2009, 50:5-14.
2. Adolphs R. The neurobiology of social cognition. Curr. Opin. Neurobiol. 2001, 11:231-239.
3. Amodio D.M., Frith C.D. Meeting of minds: the medial frontal cortex and social cognition. Nat. Rev. Neurosci. 2006, 7:268-277.
4. Archer J., Hay D.C., Young A.W. Movement, face processing and schizophrenia: evidence of a differential deficit in expression analysis. Br. J. Clin. Psychol. 1994, 33:45-61.
5. Audet M.C., Goulet S., Doré F.Y. Impaired social motivation and increased aggression in rats subchronically exposed to phencyclidine. Physiol. Behav. 2009, 96:394-398.
6. Baharnoori M., Bhardwaj S.K., Srivastava L.K. Neonatal behavioral changes in rats with gestational exposure to lipopolysaccharide: a prenatal infection model for developmental neuropsychiatric disorders. Schizophr. Bull. 2012, 38:444-456.
7. Becker A., Grecksch G. Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Test of predictive validity. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28:1267-1277.
8. Becker A., Grecksch G., Bernstein H.G., Höllt V., Bogerts B. Social behaviour in rats lesioned with ibotenic acid in the hippocampus: quantitative and qualitative analysis. Psychopharmacology (Berl) 1999, 144:333-338.
9. Becker A., Peters B., Schroeder H., Mann T., Huether G., Grecksch G. Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2003, 27:687-700.
10. Bellack A.S., Morrison R.L., Wixted J.T., Mueser K.T. An analysis of social competence in schizophrenia. Br. J. Psychiatry 1990, 156:809-818.
11. Ben-Ami Bartal I., Decety J., Mason P. Empathy and pro-social behavior in rats. Science 2011, 334:1427-1430.
12. Bernstein H.G., Stanarius A., Baumann B., Henning H., Krell D., Danos P., Falkai P., Bogerts B. Nitric oxide synthase-containing neurons in the human hypothalamus: reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics. Neuroscience 1998, 83:867-875.
13. Berntson G.G., Schumacher K.M. Effects of cerebellar lesions on activity, social interactions, and other motivated behaviors in the rat. J. Comp. Physiol. Psychol. 1980, 1980(94):706-717.
14. Binder J., Albus M., Hubmann W., Scherer J., Sobizack N., Franz U., Mohr F., Hecht S. Neuropsychological impairment and psychopathology in first-episode schizophrenic patients related to the early course of illness. Eur. Arch. Psychiatry Clin. Neurosci. 1998, 248:70-77.
15. Bitanihirwe B.K., Peleg-Raibstein D., Mouttet F., Feldon J., Meyer U. Late prenatal immune activation in mice leads to behavioral and neurochemical abnormalities relevant to the negative symptoms of schizophrenia. Neuropsychopharmacology 2010, 35:2462-2478.
16. Breier A., Schreiber J.L., Dyer J., Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia: prognosis and predictors of outcome. Arch. Gen. Psychiatry 1991, 48:239-246.
17. Brixey S.N., Gallagher B.J., McFalls J.A., Parmelee L.F. Gestational and neonatal factors in the etiology of schizophrenia. J. Clin. Psychol. 1993, 149:447-456.
18. Bruins Slot L., Kleven M.S., Newman-Tancredi A. Effects of novel antipsychotics with mixed D2 antagonist/5-HT1A agonist properties on PCP induced social interaction deficits in the rat. Neuropharmacology 2005, 49:996-1006.
19. Calcagnetti D.J., Schechter M.D. Place conditioning reveals the rewarding aspect of social interaction in juvenile rats. Physiol. Behav. 1992, 51:667-672.
20. Cannon M., Jones P., Gilvarry C., Rifkin L., McKenzie K., Foerster A., Murray R.M. Premorbid social functioning in schizophrenia and bipolar disorder: similarities and differences. Am. J. Psychiatry 1997, 154:1544-1550.
21. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., Carlsson M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu. Rev. Pharmacol. Toxicol. 2001, 41:237-260.
22. Carpenter W.T., Koenig J.I. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology 2008, 33:2061-2079.
23. Carter C.S., Grippo A.J., Pournajafi-Nazarloo H., Ruscio M.G., Porges S.W. Oxytocin, vasopressin and sociality. Prog. Brain Res. 2008, 170:331-336.
24. Chen Q., Panksepp J.B., Lahvis G.P. Empathy is moderated by genetic background in mice. PLoS One 2009, 4:e4387.
25. Corbett R., Fielding S., Cornfeldt M., Dunn R.W. GABAmimetic agents display anxiolytic-like effects in the social interaction and elevated plus maze procedures. Psychopharmacology (Berl) 1991, 104:312-316.
26. Corrigan P.W., Addis I.B. The effect of cognitive complexity on a social sequencing task in schizophrenia. Schizophr. Res. 1995, 16:137-144.
27. Corrigan P.W., Green M.F. Schizophrenic patients' sensitivity to social cues: the role of abstraction. Am. J. Psychiatry. 1993, 150:589-594.
28. Cullen K., Guimaraes A., Wozniak J., Anjum A., Schulz S.C., White T. Trajectories of social withdrawal and cognitive decline in the schizophrenia prodrome. Clin. Schizophr. Relat. Psychos. 2011, 4:229-238.
29. de Moura Linck V., Herrmann A.P., Goerck G.C., Iwu M.M., Okunji C.O., Leal M.B., Elisabetsky E. The putative antipsychotic alstonine reverses social interaction withdrawal in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1449-1452.
30. Deacon R.M., Bannerman D.M., Rawlins J.N. Anxiolytic effects of cytotoxic hippocampal lesions in rats. Behav. Neurosci. 2002, 116:494-497.
31. DeLisi L.E. Speech disorder in schizophrenia: review of the literature and exploration of its relation to the uniquely human capacity for language. Schizophr. Bull. 2001, 27:481-496.
32. Der-Avakian A., Markou A. Withdrawal from chronic exposure to amphetamine, but not nicotine, leads to an immediate and enduring deficit in motivated behavior without affecting social interaction in rats. Behav. Pharmacol. 2010, 21:359-368.
33. Desbonnet L., O'Tuathaigh C.M., Waddington J.L. Modeling schizophrenia: uncovering novel therapeutic targets. Expert Rev. Clin. Pharmacol. 2012, 5:667-676.
34. Dluzen D.E., Muraoka S., Engelmann M., Landgraf R. The effects of infusion of arginine vasopressin, oxytocin, or their antagonists into the olfactory bulb upon social recognition responses in male rats. Peptides 1998, 19:999-1005.
35. Dluzen D.E., Muraoka S., Landgraf R. Olfactory bulb norepinephrine depletion abolishes vasopressin and oxytocin preservation of social recognition responses in rats. Neurosci. Lett. 1998, 254(3):161-164.
36. Ellenbroek B.A., Cools A.R. Animal models for the negative symptoms of schizophrenia. Behav. Pharmacol. 2000, 11:223-233.
37. Engelmann M., Wotjak C.T., Landgraf R. Social discrimination procedure: an alternative method to investigate juvenile recognition abilities in rats. Physiol. Behav. 1995, 58:315-321.
38. Erhart S.M., Marder S.R., Carpenter W.T. Treatment of schizophrenia negative symptoms: future prospects. Schizophr. Bull. 2006, 32:234-237.
39. Feifel D., Mexal S., Melendez G., Liu P.Y., Goldenberg J.R., Shilling P.D. The brattleboro rat displays a natural deficit in social discrimination that is restored by clozapine and a neurotensin analog. Neuropsychopharmacology 2009, 34:2011-2018.
40. Fenton W.S., McGlashan T.H. Natural history of schizophrenia subtypes: II. positive and negative symptoms and longterm course. Arch. Gen. Psychiatry 1991, 48:978-986.
41. Fernandez Espejo E. Prefrontocortical dopamine loss in rats delays long-term extinction of contextual conditioned fear, and reduces social interaction without affecting short-term social interaction memory. Neuropsychopharmacology 2003, 28:490-498.
42. File S.E. The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J. Neurosci. Methods 1980, 2:219-238.
43. File S.E., Hyde J.R. Can social interaction be used to measure anxiety?. Br. J. Pharmacol. 1978, 62:19-24.
44. File S.E., James T.A., MacLeod N.K. Depletion in amygdaloid 5-hydroxytryptamine concentration and changes in social and aggressive behaviour. J. Neural Transm. 1981, 50:1-12.
45. File S.E., Seth P. A review of 25 years of the social interaction test. Eur. J. Pharmacol. 2003, 463:35-53.
46. Flagstad P., Mørk A., Glenthøj B.Y., van Beek J., Michael-Titus A.T., Didriksen M. Disruption of neurogenesis on gestational day 17 in the rat causes behavioral changes relevant to positive and negative schizophrenia symptoms and alters amphetamine-induced dopamine release in nucleus accumbens. Neuropsychopharmacology 2004, 29:2052-2064.
47. Floresco S.B., Geyer M.A., Gold L.H., Grace A.A. Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia. Schizophr. Bull. 2005, 31:888-894.
48. Frith U., Happé F. Language and communication in autistic disorders. Philos. Trans. R. Soc. Lond. B Biol. Sci. 1994, 346:97-104.
49. Gambill J.D., Kornetsky C. Effects of chronic d-amphetamine on social behavior of the rat: implications for an animal model of paranoid schizophrenia. Psychopharmacology (Berl) 1976, 50:215-223.
50. Goghari V.M., Sponheim S.R., MacDonald A.W. The functional neuroanatomy of symptom dimensions in schizophrenia: a qualitative and quantitative review of a persistent question. Neurosci. Biobehav. Rev. 2010, 34:468-486.
51. Gonzalez L.E., Andrews N., File S.E. 5-HT1A and benzodiazepine receptors in the basolateral amygdala modulate anxiety in the social interaction test, but not in the elevated plus-maze. Brain Res. 1996, 732:145-153.
52. Gonzalez L.E., Ouagazzal A.M., File S.E. Stimulation of benzodiazepine receptors in the dorsal hippocampus and median raphé reveals differential GABAergic control in two animal tests of anxiety. Eur. J. Neurosci. 1998, 10:3673-3680.
53. Gonzalez L.E., Rujano M., Tucci S., Paredes D., Silva E., Alba G., Hernandez L. Medial prefrontal transection enhances social interaction. I: behavioral studies. Brain Res. 2000, 887:7-15.
54. Goodwin G.A., Molina V.A., Spear L.P. Repeated exposure of rat pups to isolation attenuates isolation-induced ultrasonic vocalization rates: reversal with naltrexone. Dev. Psychobiol. 1994, 27:53-64.
55. Greig T.C., Bryson G.J., Bell M.D. Theory of mind performance in schizophrenia: diagnostic, symptom, and neuropsychological correlates. J. Nerv. Ment. Dis. 2004, 192:12-18.
56. Gur R.E., Kohler C., Turetsky B.I., Siegel S.J., Kanes S.J., Bilker W.B., Brennan A.R., Gur R.C. A sexually dimorphic ratio of orbitofrontal to amygdala volume is altered in schizophrenia. Biol. Psychiatry 2004, 55:512-517.
57. Gur R.E., McGrath C., Chan R.M., Schroeder L., Turner T., Turetsky B.I., Kohler C., Alsop D., Maldjian J., Ragland J.D., Gur R.C. An fMRI study of facial emotion processing in patients with schizophrenia. Am. J. Psychiatry 2002, 159:1992-1999.
58. Gururajan A., Taylor D.A., Malone D.T. Current pharmacological models of social withdrawal in rats: relevance to schizophrenia. Behav. Pharmacol. 2010, 21(8):690-709.
59. Gururajan A., Taylor D.A., Malone D.T. Effect of cannabidiol in a MK-801-rodent model of aspects of schizophrenia. Behav. Brain Res. 2011, 222:299-308.
60. Guy A.P., Gardner C.R. Pharmacological characterisation of a modified social interaction model of anxiety in the rat. Neuropsychobiology 1985, 13:194-200.
61. Habel U., Windischberger C., Derntl B., Robinson S., Kryspin-Exner I., Gur R.C., Moser E. Amygdala activation and facial expressions: explicit emotion discrimination versus implicit emotion processing. Neuropsychologia 2007, 45:2369-2377.
62. Haller J., Szirmai M., Varga B., Ledent C., Freund T.F. Cannabinoid CB1 receptor dependent effects of the NMDA antagonist phencyclidine in the social withdrawal model of schizophrenia. Behav. Pharmacol. 2005, 16:415-422.
63. Harich S., Gross G., Bespalov A. Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment. Psychopharmacology (Berl) 2007, 192:511-519.
64. Harvey P.D., Koren D., Reichenberg A., Bowie C.R. Negative symptoms and cognitive deficits: what is the nature of their relationship?. Schizophr. Bull. 2006, 32:250-258.
65. Hashimoto T., Volk D.W., Eggan S.M., Mirnics K., Pierri J.N., Sun Z., Sampson A.R., Lewis D.A. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J. Neurosci. 2003, 23:6315-6326.
66. Humphreys A.P., Einon D.F. Play as a reinforcer for maze learning in juvenile rats. Anim. Behav. 1981, 29:259-270.
67. Javitt D.C. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J. Clin Psychiatry 1987, 9:12-35.
68. Javitt D.C. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Int. Rev. Neurobiol. 2007, 78:69-108.
69. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991, 140:1301-1308.
70. Kaidanovich-Beilin O., Lipina T., Vukobradovic I., Roder J., Woodgett J.R. Assessment of social interaction behaviors. J. Vis. Exp. 2011, (48). 10.3791/2473.
71. Katschnig H. Schizophrenia and quality of life. Acta Psychiatr. Scand. 2000, 407(suppl):33-37.
72. Keefe R.S., Harvey P.D., Lenzenweger M.F., Davidson M., Apter S.H., Schmeidler J., Mohs R.C., Davis K.L. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetaipaine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr. Res. 1999, 35:51-68.
73. Kirkpatrick B., Fenton W.S., Carpenter W.T., Marder S.R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr. Bull. 2006, 32:214-219.
74. Kirsten T.B., Taricano M., Maiorka P.C., Palermo-Neto J., Bernardi M.M. Prenatal lipopolysaccharide reduces social behavior in male offspring. Neuroimmunomodulation 2010, 17:240-251.
75. Knutson B., Burgdorf J., Panksepp J. Anticipation of play elicits high-frequency ultrasonic vocalizations in young rats. J. Comp. Psychol. 1998, 112:65-73.
76. Krystal J.H., Karper L.P., Seibyl J.P. Subanaesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51:199-214.
77. Lahti A.C., Holcomb H.H., Medoff D.R., Tamminga C.A. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 1995, 6:869-872.
78. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995, 13:9-19.
79. Lancaster K., Dietz D.M., Moran T.H., Pletnikov M.V. Abnormal social behaviors in young and adult rats neonatally infected with Borna disease virus. Behav. Brain Res. 2007, 176:141-148.
80. Lee P.R., Brady D.L., Shapiro R.A., Dorsa D.M., Koenig J.I. Prenatal stress generates deficits in rat social behavior: reversal by oxytocin. Brain Res. 2007, 1156:152-167.
81. Lee P.R., Brady D.L., Shapiro R.A., Dorsa D.M., Koenig J.I. Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin. Neuropsychopharmacology 2005, 30:1883-1894.
82. Leucht S., Kissling W., Davis J.M. Second-generation antipsychotics for schizophrenia: can we resolve the conflict?. Psychol. Med. 2009, 39:1591-1602.
83. Leucht S., Pitschel-Walz G., Abraham D., Kissling W. Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone and sertindole compared to conventional antipsychotics and placebo. A metaanalysis of randomized controlled trials. Schizophr. Res. 1999, 35:51-68.
84. Lewis D.A., Hashimoto T., Volk D.W. Cortical inhibitory neurons and schizophrenia. Nature Rev. Neurosci. 2005, 6:312-324.
85. Li M., He W., Heupel K. Administration of clozapine to a mother rat potentiates pup ultrasonic vocalization in response to separation and re-separation: contrast with haloperidol. Behav. Brain Res. 2011, 222:385-389.
86. Lindenmayer J.P. New pharmacotherapeutic modalities for negative symptoms in psychosis. Acta Psychiatr. Scand. 1995, 388(Suppl):15-19.
87. Lipina T.V., Fletcher P.J., Lee F.H., Wong A.H., Roder J.C. Disrupted-in-schizophrenia-1 Gln31Leu polymorphism results in social anhedonia associated with monoaminergic imbalance and reduction of CREB and β-arrestin-1,2 in the nucleus accumbens in a mouse model of depression. Neuropsychopharmacology 2013, 38:423-436.
88. Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., Kelley R. Study of a new schizophrenomimetic drug; sernyl. AMA Arch. Neurol. Psychiatry 1959, 81:363-369.
89. Lukkes J.L., Mokin M.V., Scholl J.L., Forster G.L. Adult rats exposed to early-life social isolation exhibit increased anxiety and conditioned fear behavior, and altered hormonal stress responses. Horm. Behav. 2009, 55(1):248-256.
90. Mai J.K., Berger K., Sofroniew M.V. Morphometric evaluation of neurophysin-immunoreactivity in the human brain: pronounced inter-individual variability and evidence for altered staining patterns in schizophrenia. J. Hirnforsch. 1993, 34:133-154.
91. Malhotra K.A., Pinals A.D., Adler M.C., Elman I., Clifton A., Pickar D., Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997, 17:141-150.
92. Markham J.A., Koenig J.I. Prenatal stress: role in psychotic and depressive diseases. Psychopharmacology (Berl) 2011, 214:89-106.
93. Matrisciano F., Tueting P., Maccari S., Nicoletti F., Guidotti A. Pharmacological activation of group-II metabotropic glutamate receptors corrects a schizophrenia-like phenotype induced by prenatal stress in mice. Neuropsychopharmacology 2012, 37:929-938.
94. Matsuoka T., Tsunoda M., Sumiyoshi T., Takasaki I., Tabuchi Y., Seo T., Tanaka K., Uehara T., Itoh H., Suzuki M., Kurachi M. Effect of MK-801 on gene expressions in the amygdala of rats. Synapse 2008, 62:1-7.
95. Meaney M.J., Stewart J. A descriptive study of social development in the rat (Rattus norvegicus). Anim. Behav. 1981, 29:34-45.
96. Meng Q., Li N., Han X., Shao F., Wang W. Peri-adolescence isolation rearing alters social behavior and nociception in rats. Neurosci. Lett. 2010, 480(1):25-29.
97. Morrison R.L., Bellack A.S. Social functioning of schizophrenic patients: clinical and research issues. Schizophr. Bull. 1987, 13:715-725.
98. Moy S.S., Nadler J.J. Advances in behavioral genetics: mouse models of autism. Mol. Psychiatry 2008, 13:4-26.
99. Moy S.S., Nadler J.J., Perez A., Barbaro R.P., Johns J.M., Magnuson T.R., Piven J., Crawley J.N. Sociability and preference for social novelty in five inbred strains: an approach to assess autistic-like behavior in mice. Genes Brain Behav. 2004, 3:287-302.
100. Nadler J.J., Moy S.S., Dold G., Trang D., Simmons N., Perez A., Young N.B., Barbaro R.P., Piven J., Magnuson T.R., Crawley J.N. Automated apparatus for quantitation of social approach behaviors in mice. Genes Brain Behav. 2004, 3:303-314.
101. Nakatani-Pawlak A., Yamaguchi K., Tatsumi Y., Mizoguchi H., Yoneda Y. Neonatal phencyclidine treatment in mice induces behavioral, histological and neurochemical abnormalities in adulthood. Biol. Pharm. Bull. 2009, 32:1576-1583.
102. Neill J.C., Barnes S., Cook S., Grayson B., Idris N.F., McLean S.L., Snigdha S., Rajagopal L., Harte M.K. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol. Ther. 2010, 128:419-432.
103. Nestler E.J., Hyman S.E. Animal models of neuropsychiatric disorders. Nat. Neurosci. 2010, 13:1161-1169.
104. Norman R.M., Malla A.K., McLean T., Voruganti L.P., Cortese L., McIntosh E., Cheng S., Rickwood A. The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the quality of life scale. Acta Psychiatr. Scand. 2000, 102:303-309.
105. Panksepp J., Beatty W.W. Social deprivation and play in rats. Behav. Neural Biol. 1980, 30:197-206.
106. Panksepp J.B., Jochman K.A., Kim J.U., Koy J.J., Wilson E.D., Chen Q., Wilson C.R., Lahvis G.P. Affiliative behavior, ultrasonic communication and social reward are influenced by genetic variation in adolescent mice. PLoS One 2007, 2:e351.
107. Panksepp J.B., Lahvis G.P. Social reward among juvenile mice. Genes Brain Behav. 2007, 6:661-671.
108. Panksepp J.B., Lahvis G.P. Rodent empathy and affective neuroscience. Neurosci. Biobehav. Rev. 2011, 35:1864-1875.
109. Patterson P.H. Modeling autistic features in animals. Pediatr. Res. 2011, 69(5 Pt 2):34R-40R.
110. Pogue-Geile M.F., Harrow M. Negative symptoms in schizophrenia: their longitudinal course and prognostic importance. Schizophr. Bull. 1985, 11:427-439.
111. Popik P., van Ree J.M. Oxytocin but not vasopressin facilitates social recognition following injection into the medial preoptic area of the rat brain. Eur. Neuropsychopharmacol. 1991, 1:555-560.
112. Puig O., Penadés R., Gastó C., Catalán R., Torres A., Salamero M. Verbal memory, negative symptomatology and prediction of psychosocial functioning in Schizophrenia. Psychiatry Res. 2008, 158:11-17.
113. Qiao H., Noda Y., Kamei T., Nagai T., Furukawa H., Miura H., Kayukawa Y., Ohta T., Nabeshima T. Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment. NeuroReport 2001, 12:11-15.
114. Rung J.P., Carlsson A., Rydén Markinhuhta K., Carlsson M.L. (+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2005, 29:827-832.
115. Sams-Dodd F. Automation of the social interaction test by a video-tracking system: behavioural effects of repeated phencyclidine treatment. J. Neurosci. Methods 1995, 59:157-167.
116. Sams-Dodd F. Distinct effects of d-amphetamine and phencyclidine on the social behaviour of rats. Behav. Pharmacol. 1995, 6:55-65.
117. Sams-Dodd F. Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav. Pharmacol. 1996, 7:3-23.
118. Sams-Dodd F. Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test. Behav. Pharmacol. 1997, 8:196-215.
119. Sams-Dodd F. A test of the predictive validity of animal models of schizophrenia based on phencyclidine and D-amphetamine. Neuropsychopharmacology 1998, 18(4):293-304.
120. Sams-Dodd F., Lipska B.K., Weinberger D.R. Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood. Psychopharmacology (Berl) 1997, 132:303-310.
121. Schwabe K., Klein S., Koch M. Behavioural effects of neonatal lesions of the medial prefrontal cortex and subchronic pubertal treatment with phencyclidine of adult rats. Behav. Brain Res. 2006, 168:150-160.
122. 1 receptors: implications for schizophrenia. Neuropsychopharmacology 2013, 38(9):1816-1824.
123. Shah A.A., Treit D. Excitotoxic lesions of the medial prefrontal cortex attenuate fear responses in the elevated-plus maze, social interaction and shock probe burying tests. Brain Res. 2003, 969:183-194.
124. Shair H.N. Acquisition and expression of a socially mediated separation response. Behav. Brain Res. 2007, 182:180-192.
125. Shi L., Fatemi S.H., Sidwell R.W., Patterson P.H. Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. J. Neurosci. 2003, 23:297-302.
126. Shimazaki T., Kaku A., Chaki S. D-Serine and a glycine transporter-1 inhibitor enhance social memory in rats. Psychopharmacology (Berl) 2010, 209:263-270.
127. Silvestre J.S., Nadal R., Pallarés M., Ferré N. Acute effects of ketamine in the holeboard, the elevated-plus maze, and the social interaction test in Wistar rats. Depress. Anxiety 1997, 5:9-33.
128. Snigdha S., Neill J.C. Efficacy of antipsychotics to reverse phencyclidine induced social interaction deficits in female rats - a preliminary investigation. Behav. Brain Res. 2008, 187:489-494.
129. Snyder S.H. Catecholamines in the brain as mediators of amphetamine psychosis. Arch. Gen. Psychiatry 1972, 27(2):169-179.
130. Snyder S.H. Amphetamine psychosis: a "model" schizophrenia mediated by catecholamines. Am. J. Psychiatry 1973, 130:61-67.
131. Steinpreis R.E., Sokolowski J.D., Papanikolaou A., Salamone J.D. The effects of haloperidol and clozapine on PCP- and amphetamine-induced suppression of social behavior in the rat. Pharmacol. Biochem. Behav. 1994, 47:579-585.
132. Stewart R.B., Grupp L.A. Some determinants of the motivational properties of ethanol in the rat: concurrent administration of food or social stimuli. Psychopharmacology (Berl) 1985, 87:43-50.
133. Swartz M.S., Perkins D.O., Stroup T.S., Davis S.M., Capuano G., Rosenheck R.A., Reimherr F., McGee M.F., Keefe R.S., McEvoy J.P., Hsiao J.K., Lieberman J.A., CATIE Investigators Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am. J. Psychiatry 2007, 164:428-436.
134. Tandon R., Nasrallah H.A., Keshavan M.S. Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future. Schizophr. Res. 2010, 122:1-23.
135. Thomsen M.S., Christensen D.Z., Hansen H.H., Redrobe J.P., Mikkelsen J.D. Alpha(7) Nicotinic acetylcholine receptor activation prevents behavioral and molecular changes induced by repeated phencyclidine treatment. Neuropharmacology 2009, 56(6-7):1001-1009.
136. Thurmond J.B. Technique for producing and measuring territorial aggression using laboratory mice. Physiol. Behav. 1975, 14:879-881.
137. Trezza V., Damsteegt R., Manduca A., Petrosino S., Van Kerkhof L.W., Pasterkamp R.J., Zhou Y., Campolongo P., Cuomo V., Di Marzo V., Vanderschuren L.J. Endocannabinoids in amygdala and nucleus accumbens mediate social play reward in adolescent rats. J. Neurosci. 2012, 32:14899-14908.
138. Tzschentke T.M. Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict. Biol. 2007, 12:227-462.
139. Uribe E., Landaeta J., Wix R., Eblen A. Memantine reverses social withdrawal induced by ketamine in rats. Exp. Neurobiol. 2013, 22(1):18-22.
140. Van den Berg C.L., Van Ree J.M., Spruijt B.M., Kitchen I. Effects of juvenile isolation and morphine treatment on social interactions and opioid receptors in adult rats: behavioural and autoradiographic studies. Eur. J. Neurosci. 1999, 11(9):3023-3032.
141. Van den Buuse M., Garner B., Gogos A., Kusljic S. Importance of animal models in schizophrenia research. Aust. N Z. J. Psychiatry 2005, 39:550-557.
142. Vanderschuren L.J., Niesink R.J., Van Ree J.M. The neurobiology of social play behavior in rats. Neurosci. Biobehav. Rev. 1997, 21:309-326.
143. Volkmar F.R. Understanding the social brain in autism. Dev. Psychobiol. 2011, 53:428-434.
144. von Heimendahl M., Rao R.P., Brecht M. Weak and nondiscriminative responses to conspecifics in the rat hippocampus. J. Neurosci. 2012, 32:2129-2141.
145. Weaver I.C., Meaney M.J., Szyf M. Maternal care effects on the hippocampal transcriptome and anxiety-mediated behaviors in the offspring that are reversible in adulthood. Proc. Natl. Acad. Sci. USA 2006, 103:3480-3485.
146. White I.M., Minamoto T., Odell J.R., Mayhorn J., White W. Brief exposure to methamphetamine (METH) and phencyclidine (PCP) during late development leads to long-term learning deficits in rats. Brain Res. 2009, 1266:72-86.
147. Wilson C., Terry A.V. Neurodevelopmental animal models of schizophrenia: role in novel drug discovery and development. Clin. Schizophr. Relat. Psychos. 2010, 4:124-137.
148. Wilson C.A., Vazdarjanova A., Terry A.V. Exposure to variable prenatal stress in rats: effects on anxiety-related behaviors, innate and contextual fear, and fear extinction. Behav. Brain Res. 2013, 238:279-288.
149. Wykes T., Steel C., Everitt B., Tarrier N. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr. Bull. 2008, 34:523-537.
150. Yee N., Schwarting R.K., Fuchs E., Wöhr M. Increased affective ultrasonic communication during fear learning in adult male rats exposed to maternal immune activation. J. Psychiatr. Res. 2012, 46:1199-1205.
151. Yeganeh-Doost P., Gruber O., Falkai P., Schmitt A. The role of the cerebellum in schizophrenia: from cognition to molecular pathways. Clinics (Sao Paulo) 2011, 66:71-77.
152. Yizhar O. Optogenetic insights into social behavior function. Biol. Psychiatry 2012, 71:1075-1080.
153. Yizhar O., Fenno L.E., Prigge M., Schneider F., Davidson T.J., O'Shea D.J., Sohal V.S., Goshen I., Finkelstein J., Paz J.T., Stehfest K., Fudim R., Ramakrishnan C., Huguenard J.R., Hegemann P., Deisseroth K. Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature 2011, 477:171-178.
154. Zhao X., Sun L., Jia H., Meng Q., Wu S., Li N., He S. Isolation rearing induces social and emotional function abnormalities and alters glutamate and neurodevelopment-related gene expression in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33(7):1173-1177.
155. Zou H., Zhang C., Xie Q., Zhang M., Shi J., Jin M., Yu L. Low dose MK-801 reduces social investigation in mice. Pharmacol. Biochem. Behav. 2008, 90:753-757.